• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    With Fermion, start the journey of your innovative API.

    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing

    GLOBENEWSWIRE

    Castle Biosciences Partners with Sci Base for Dermatologic Tests

    GLOBENEWSWIRE

    Castle Biosciences CEO Derek Maetzold to Join Panel at 2025 BIO

    GLOBENEWSWIRE

    Castle Biosciences CEO Derek Maetzold Wins Lifetime Achievement A

    GLOBENEWSWIRE

    ASCO 2025: DecisionDx®-Melanoma Improves Risk Stratification

    GLOBENEWSWIRE

    Castle Biosciences to Present at 2025 Jefferies Global Conference

    GLOBENEWSWIRE

    Real-World Study Confirms DecisionDx-UM for Uveal Melanoma

    GLOBENEWSWIRE

    Castle Biosciences Celebrates Skin Cancer Awareness Month

    GLOBENEWSWIRE

    Castle Biosciences to Acquire Previse

    GLOBENEWSWIRE

    Castle Biosciences Reports First Quarter 2025 Results

    GLOBENEWSWIRE

    DDW 2025 Data Shows TissueCypher® Test Identifies Esophageal Canc

    GLOBENEWSWIRE

    Castle Dx Test Outperforms in Melanoma Node Risk

    GLOBENEWSWIRE

    DecisionDx-Melanoma Test Tops 200K Orders for Patients

    GLOBENEWSWIRE

    Data at AACR Shows DecisionDx Melanoma Predicts Metastasis

    GLOBENEWSWIRE

    Castle Biosciences to Release Q1 2025 Results, Host Call May 5

    GLOBENEWSWIRE

    Castle Biosciences Strengthens Esophageal Cancer Awareness Commit

    GLOBENEWSWIRE

    Castle Biosciences Wins Top Workplaces USA Award 4th Year

    GLOBENEWSWIRE

    Study Shows Positive Outcomes in Low-Risk Melanoma Patients

    GLOBENEWSWIRE

    Castle Bio`s DecisionDx-Melanoma Test Supports Risk-Based Care

    GLOBENEWSWIRE

    Castle Bio` DecisionDx®-SCC Data Top Five Abstract at NCCN 2025

    GLOBENEWSWIRE

    Castle Biosciences Dermatology Data To Be Presented At AAD 2025

    BUSINESSWIRE

    Castle Biosciences Reports Q4 and Full-Year 2024 Results

    BUSINESSWIRE

    Castle Bio to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Castle To Present Dermatologic Gene Test Data At Winter Clinical

    BUSINESSWIRE

    Castle Bio Highlights Progress on Atopic Dermatitis Gene Test

    BUSINESSWIRE

    Castle Bio Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Castle`s DecisionDx®-Melanoma Aids Melanoma Management

    BUSINESSWIRE

    Castle Bio to Present at Piper Sandler Healthcare Conference

    BUSINESSWIRE

    Castle Bio Presents Melanoma Data at Dermatopathology 66th Meeting

    BUSINESSWIRE

    Castle Biosciences’ Test Reduces Unnecessary SLNB Procedures

    BUSINESSWIRE

    Castle Biosciences to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Castle Bio Presents CONNECTION Study Data for DecisionDx®-Melanoma

    BUSINESSWIRE

    Publications Affirm Gene Profile Testing In Melanocytic Lesions

    BUSINESSWIRE

    Castle Biosciences` DecisionDx-SCC Test Data Presented At ASTRO

    BUSINESSWIRE

    Castle Biosciences Reports Second Quarter 2024 Results

    BUSINESSWIRE

    Castle Biosciences turns to former ‘Real Housewife’ for melanoma campaign

    FIERCE PHARMA

    Castle Bio And Teddi Mellencamp Launch Melanoma Awareness Campaign

    BUSINESSWIRE

    DecisionDx-SCC Identifies High-Risk SCC Patients For Adjuvant Radiation

    BUSINESSWIRE

    Castle Expands Barrett`s Test Evidence At DDW 2024

    BUSINESSWIRE

    Castle IDgenetix Named Best Mental Health Solution 2024

    BUSINESSWIRE

    Castle Biosciences Reports First Quarter 2024 Results

    BUSINESSWIRE

    Presentations of Castle Bio DecisionDx®-Melanoma and DecisionDx®-SCC Tests

    BUSINESSWIRE

    Castle Biosciences Announces Updates to its Board of Directors

    BUSINESSWIRE

    New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

    BUSINESSWIRE

    Castle Biosciences to Present at the KeyBanc Capital Markets Forum

    BUSINESSWIRE

    Castle to Present Data Highlighting the Value of its Dermatologic Tests

    BUSINESSWIRE

    Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

    BUSINESSWIRE

    Castle`s COO Kristen Oelschlager Selected Among the Top 25 Women Leaders in Bio

    BUSINESSWIRE

    Castle Biosciences Announces Multiple Data Presentations at Annual Meeting

    BUSINESSWIRE

    Data Shows Ability of Castle Biosciences’ Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

    BUSINESSWIRE

    Castle Biosciences to Release Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Castle Biosciences Presents New Data at ASTRO 2023

    BUSINESSWIRE

    Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression

    BUSINESSWIRE

    Castle to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

    BUSINESSWIRE

    Castle Biosciences Reports Second Quarter 2023 Results

    BUSINESSWIRE

    Castle Biosciences to Release Second Quarter 2023 Financial Results

    PRESS RELEASE

    Castle Biosciences to Host Second Annual Castle Cares Charity Walk

    BUSINESSWIRE

    Castle Honored as an Arizona Top Workplace for the Second Consecutive Year

    PRESS RELEASE

    Castle to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at AHNS

    PRESS RELEASE

    IDgenetix® Shown to Significantly Improve Medication Response

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.